Join us   Log in  

PHARMASPIRE - Volume 10, Issue 2, April - June, 2018

Pages: 55-63

Date of Publication: 14-Jun-2022

Print Article   Download XML  Download PDF

Recent trends in ocular drug delivery

Author: Amandeep Singh, Deepa Negi , Neeraj Mishra , Ashish Baldi

Category: Pharmaceutics


The eye preparations are sterile, isotonic solution, and buffered solutions. They are used for instant action. They cannot retain for the long time period. It is the major drawback with the conventional eyes dosage form; they are not able to maintain a therapeutic level. Ophthalmic preparation should be free from non-irritant and physiological properties of the material should not affect the physiological condition of the eye, not shown any type blurred vision. To attain the therapeutic effect with prolong action, this can be possible with novel drug delivery system. Ocular insert name is given to preparations which are controlled in the release as well as maintain the therapeutic level of drug in the eye conventional, mostly eye drops are used but due to lack of longer action preparations are modified in the form of ocular inserts. Various novel drug delivery systems have been developed to attain the better therapeutic effect of the drug. This article will cover the recent advancement of ocular to exploit better patient compliance and improved therapeutic efficacy.

Keywords: Bioavailability, BODS, corneal permeability, eye, new ophthalmic delivery system, particulate system, polymer, topical inserts


1. Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ. Associations between signs and symptoms of dry eye disease: A systematic review. Clin Ophthalmol 2015;9:1719-30.

2. Alves M, Fonseca EC, Alves MF, Malki LT, Arruda GV, Reinach PS, et al. Dry eye disease treatment: A systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf 2013;11:181-92.

3. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348-60.

4. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333-8.

5. Molokhia SA, Thomas SC, Garff KJ, Mandell KJ, Wirostko BM. Anterior eye segment drug delivery systems: Current treatments and future challenges. J Ocular Pharm Ther 2013;29:92-105.

6. Patel P, Shastri D, Shelat P, Shukla A. Ophthalmic drug delivery system: Challenges and approaches. Syst Rev Pharm 2010;1:113.

7. Zaki I, Fitzgerald P, Hardy JG, Wilson CG. A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man. J Pharm Pharmacol 1986;38:463-6.

8. Singh V, Ahmad R, Heming T. The challenges of ophthalmic drug delivery: A review. Int J Drug Disc 2011;3:56-62.

9. Schoenwald RD. Ocular pharmacokinetics/pharmacodynamics. Drugs Pharm Sci 1993;58:83-110.

10. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14.

11. Del Monte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg 2011;37:588-98.

12. Addo E, Bamiro OA, Siwale R. Anatomy of the Eye and Common Diseases Affecting the Eye. USA: Springer International Publishing AG; 2016.

13. Kaplan HJ. Anatomy and Function of the Eye. In: Immune Response and the Eye. Vol. 92. Basel: Karger Publishers; 2007. p. 4-10.

14. Willoughby CE, Ponzin D, Ferrari S, Lobo A, Landau K, Omidi Y. Anatomy and physiology of the human eye: Effects of mucopolysaccharidoses disease on structure and function–a review. Clin Exp Ophthalmol 2010;38:2-11.

15. Garhart C, Lakshminarayanan V. Anatomy of the Eye. In: Handbook of Visual Display Technology. Berlin Heidelberg: Springer; 2012. p. 73-83.

16. Wilmer HA, Scammon RE. Growth of the Components of the Human Eyeball: I. diagrams, calculations, computation and reference tables. Arch Ophthalmol 1950;43:599-619.

17. Syed BA, Kumar S, Bielory L. Current options and emerging therapies for anterior ocular inflammatory disease. Curr Opin Allergy Clin Immunol 2014;14:485-9.

18. Artal P, Guirao A. Contributions of the cornea and the lens to the aberrations of the human eye. Optics Lett 1998;23:1713-5.

19. Atchison DA, Smith G, Smith G. Optics of the Human Eye. Oxford: Butterworth-Heinemann; 2000.

20. Snell RS, Lemp MA. Clinical Anatomy of the Eye. Verlag: John Wiley & Sons; 2013.

21. Mason H, editor. Anatomy and Physiology of the Eye. Birmingham: School of Education, University of Birmingham; 1993.

22. Checcucci A. Anatomy and Physiology of the Eye. In: Light, Lasers, and Synchrotron Radiation. Boston, MA: Springer; 1991. p. 181-4.

23. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013;2:47.

24. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131-5.

25. Raviola G. The structural basis of the blood-ocular barriers. Exp Eye Res 1977;25:27-63.

26. Maurice DM, Mishima S. Ocular Pharmacokinetics. In: Pharmacology of the Eye. Berlin, Heidelberg: Springer; 1984. p. 19-116.

27. Bamiro OA, Ubale RV, Addo RT. Background of Ocular Drug Delivery. InOcular Drug Delivery: Advances, Challenges and Applications. Cham: Springer; 2016. p. 1-9.

28. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: Impacts of membranes and barriers. Exp Opin Drug Deliv 2008;5:567-81.

29. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: Challenges and opportunities. Exp Opin Biol Ther 2003;3:45-56.

30. Koevary SB. Pharmacokinetics of topical ocular drug delivery: Potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab 2003;4:213-22.

31. Mondino BJ, Brown SI, Lempert S, Jenkins MS. The acute manifestations of ocular cicatricial pemphigoid: Diagnosis and treatment. Ophthalmology 1979;86:543-52.

32. Langer R. New methods of drug delivery. Science 1990;249:1527-33.

33. Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 1999;36:3-16.

34. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 1995;16:39-43.

35. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts—advancement in therapy of eye diseases. J Adv Pharm Technol Res 2010;1:291.

36. Dave VS. Formulation Approaches for Ocular Drug Delivery. In: Nano-Biomaterials For Ophthalmic Drug Delivery. Switzerland: Springer International Publishing; 2016. p. 147-75.

37. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm 2002;28:353-69.

38. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discovery Today 2008;13:144-51.

39. Vyas SP, Mysore N, Jaitely V, Venkatesan N. Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 1998;53:466-9.

40. Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv 2011;2011. Article ID: 863734, 14 Pages.

41. Lawrence MJ. Surfactant systems: Their use in drug delivery. Chem Soc Rev 1994;23:417-24.

42. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 1995;16:61-73.

43. De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001;224:159-68. 44. Schoenwald RD. Ocular drug delivery. Clin Pharm 1990;18:255-69.

45. Ashton P, Pearson PA, Inventors; The University of Kentucky Research Foundation, Assignee. Implantable Controlled Release Device to Deliver Drugs Directly to an Internal Portion of the Body. United States Patent US 5,773,019. 1998 Jun 30.

46. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD, Ganciclovir Implant Study Group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997;337:83-90.

47. Kauper K, Nystuen A. 12 Cell therapy for ophthalmic diseases. Cell Therapy 2017;3:249.

48. Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: Use of an intravitreal device. Arch Ophthalmol 1992;110:188-95.

49. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev 1995;16:95-106.

50. Van Buskirk EM, Fraunfelder FT. Timolol and glaucoma. Arch Ophthalmol 1981;99:696.

51. Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004;45:2342-7.

52. Haimowitz C. Are contact lenses an effective vehicle for ocular-disease drug delivery? Sci J Lander Coll Arts Sci 2017;10:6.

53. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007;59:478-90.

54. Ding S. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1998;1:328-35.

55. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986;101:515-23.

56. Abdelkader H, Alany RG. Controlled and continuous release ocular drug delivery systems: Pros and cons. Curr Drug Deliv 2012;9:421-30.

57. Friess W. Collagen–biomaterial for drug delivery. Eur J Pharm Biopharm 1998;45:113-36.

58. Rathore KS, Nema RK. An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res 2009;1:1-5.

59. Diestelhorst M, Krieglstein GK. The ocular tolerability of a new ophthalmic drug delivery system (NODS). Int Ophthalmol 1994;18:1-4.

60. Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Curr Drug Deliv 2006;3:207-17.

61. Arnold RK, Inventor; Alza Corporation, Assignee. Ocular Drug Delivery Device. United States Patent US 4,014,335. 1977 Mar 29.

62. Deshpande AA, Heller J, Gurny R. Bioerodible polymers for ocular drug delivery. Crit Rev Ther Drug Carrier Syst 1998;15:381-420.

63. Davis PA, Cousins S, Inventors; University Of Miami, Assignee. Biodegradable Injectable Drug Delivery Polymer. United States Patent US 5, 384, 333. 1995 Jan 24.

64. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985;26:584-7.

65. Kearns VR, Williams RL. Drug delivery systems for the eye. Exp Rev Med Devices 2009;6:277-90.

66. Karthikeyan D, Bhowmick M, Pandey VP, Nandhakumar J, Sengottuvelu S, Sonkar S, et al. The concept of ocular inserts as drug delivery systems: An overview. Asian J Pharm (AJP) 2014;2:36.